Spring 2024 funding cycle: Applications closed, funding results available before end of May 2024
Fall 2024 funding cycle:
- Call opens: Thursday, August 29, 2024
- Deadline: Monday September 30, 2024 (2:00 pm PST)
- Funding Results: available before end of December, 2024
Amount available: $30,000 in direct costs for 1 year
Apply through the UCSF Resource Allocation Program (RAP) portal
The International Mentored Scientist Award seeks to provide a mentored career development opportunity in HIV research for international investigators affiliated with UCSF. Applicants for this award must indicate a UCSF-affiliated faculty research mentor(s) in HIV who will commit to guiding the applicant for the application process and throughout the duration of the proposed project. Project proposals should be geared toward the interests of the applicant (e.g., clinical, basic, implementation science and/or behavioral-epidemiological research) and focus on HIV research in the investigator’s home country.
Eligibility
Researchers (all levels), post-doctoral fellows, and trainees located at a UCSF-affiliated foreign institution who have not received an NIH R01- equivalent grant in HIV/AIDS are eligible. Please note that CFAR is not allowed to provide funding to any investigators who have received HIV-related R01 awards. More senior faculty members may apply only if they are newly entering the field of HIV research.
Designation of Mentor (Critical)
Mentoring is critical to the training component of the CFAR International Mentored Scientist awards. All International Mentored award applications require a faculty research mentor from UCSF or a UCSF-affiliated institution (https://cfar.ucsf.edu/about/partners). Applications without a mentor will be disqualified.
Applicants must identify their UCSF-affiliated mentors and arrange to receive mentor advice and guidance on the research portion of their application well before it is submitted (typically at least two months before the RAP deadline). CFAR is no longer available to assist with mentor identification.
Projects must be within NIH’s HIV/AIDS research high or medium priority areas. Projects in closely related areas (e.g. TB, HCV, drug use, etc.) must be clearly linked to HIV in order to be eligible for CFAR funding.
The award amount is $30,000 in direct costs for one year.
For more detailed information about this RFA, please see the RAP Portal.
International Mentored Science Awardees
36 Awards
-
Mechanisms of CD4 T-cell death among HIV-infected, HAART-treated African adults displaying poor CD4 T-cell reconstitution despite effective viral suppression
Mechanisms of CD4 T-cell death among HIV-infected, HAART-treated African adults displaying poor CD4 T-cell reconstitution despite effective viral suppression
Abstract
Most HIV-infected subjects exhibit a progressive rise in CD4 T-cell counts after initiation of highly active antiretroviral therapy (HAART). However, a subset of individuals exhibit very poor CD4 T cell recovery despite effective control of viremia. Increased activation-induced programmed cell death of CD4 T cells has been proposed as a mechanism underlying poor immune recovery. We propose to perform a nested case control study utilizing a rural cohort of HIV-infected adults whose CD4 T-cell counts have remained low (<50 cell increase) despite HAART for at least six months.
-
Evaluation of the Dynamics and Immuno-Virology of Human Papillomavirus Infections among Fishermen in Kisumu, Kenya
Evaluation of the Dynamics and Immuno-Virology of Human Papillomavirus Infections among Fishermen in Kisumu, Kenya
Abstract
Human papillomavirus (HPV) is associated with cervical, vulvar, anal and penile cancers. High incidence rates of these cancers are observed in Africa compared to other parts of the world. Severa studies have implicated that the sexual behavior of the male partner is or even more important than women?s personal sexual behavior in predicting her risk of HPV associated cancers. Little is known about the natural history of HPV infections among men; thus hampering efforts to control infection in both men and women.
-
Investigation of Pediatric HIV Disclosure in Kampala, Uganda
Investigation of Pediatric HIV Disclosure in Kampala, Uganda
Abstract
There are more than 3 million children 15 years estimated to be living with HIV, with almost 90% residing in sub-Saharan Africa (SSA). This presents a growing challenge to health providers and caregivers concerning the disclosure of HIV serostatus to infected children. Studies conducted in SSA have indicated that only 2% to 37.8% of HIV-infected children 15 years know their HIV status. Despite formal recommendations for disclosure, there are no tested models for supporting caregivers and HIV-infected children in SSA through the process of disclosure.
-
Promoting Positive Caregiver-Child Interaction Between HIV-Affected Children and Their Caregivers with Depression in Kwa-Zulu Natal, South Africa
Promoting Positive Caregiver-Child Interaction Between HIV-Affected Children and Their Caregivers with Depression in Kwa-Zulu Natal, South Africa
Abstract
Depression is a serious public health concern, due to its negative impact of women's health, their infants and their families. HIV-infected caregivers are at high risk for a range of psychiatric and emotional problems that impact medication adherence and disease progression, and negatively affect mother-infant interactions, infant and child health, and development outcomes.
-
Impact of Neonatal Exposure to Malaria and HIV on the Frequency, Phenotype, and Function of __ T Cell Subsets at Birth
Impact of Neonatal Exposure to Malaria and HIV on the Frequency, Phenotype, and Function of __ T Cell Subsets at Birth
Abstract
The Vδ2+ subset of γδ T cells possess intrinsic reactivity to malaria antigens and may be an important antimalarial effector mechanism, but there is evidence that chronic exposure to malaria and HIV is associated with the loss and dysfunction of this subset. It is unclear whether in utero exposure to malaria or HIV is associated with reduced frequencies and/or dysfunction of Vδ 2+ T cells.
-
Feasibility of Screening and Brief Intervention for Hazardous Alcohol use amongst HIV-infected Adults in Uganda: A Qualitative Study
Feasibility of Screening and Brief Intervention for Hazardous Alcohol use amongst HIV-infected Adults in Uganda: A Qualitative Study
Abstract
In sub-Saharan Africa, screening and brief intervention (SBI) to reduce alcohol consumption may improve HIV treatment outcomes in HIV-infected hazardous drinkers. However, the feasibility, efficacy and effectiveness of this intervention in this region remains unknown. We propose to carry out a qualitative study to describe the feasibility of using SBI to reduce hazardous alcohol use in HIV infected adults in Uganda.